Finance

Lists
Why is 600664 up 2,10%?
Dive Deeper
600664:SHA
Harbin Pharmaceutical Group Co Ltd
6,32 CN¥
+2,10%
(+0,13) 1D
16 հոկ, 15:00:01 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600664...
Open
6,26 CN¥
High
6,77 CN¥
Low
6,19 CN¥
Mkt. cap
15,92 մլրդ
Avg. vol.
387,14 մլն
Volume
412,40 մլն
P/E ratio
31,08
52-wk high
9,86 CN¥
52-wk low
2,84 CN¥
EPS
0,20 CN¥
Shares outstanding
2,54 մլրդ
No. of employees
10 հզր
Open
6,26 CN¥
High
6,77 CN¥
Low
6,19 CN¥
Mkt. cap
15,92 մլրդ
Avg. vol.
387,14 մլն
Volume
412,40 մլն
P/E ratio
31,08
52-wk high
9,86 CN¥
52-wk low
2,84 CN¥
EPS
0,20 CN¥
Shares outstanding
2,54 մլրդ
No. of employees
10 հզր
News stories
From web sources and news partners
Profile
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate. The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
About Harbin Pharmaceutical Group Co Ltd
CEO-
Employees10 հզր
Founded1988
Headquarters-
Sector-
Websitehayao.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
3,90 մլրդ
3,94 մլրդ
4,18 մլրդ
4,12 մլրդ
Cost of goods sold
2,95 մլրդ
2,96 մլրդ
3,17 մլրդ
2,96 մլրդ
Cost of revenue
2,95 մլրդ
2,96 մլրդ
3,17 մլրդ
2,96 մլրդ
Research and development expenses
33,63 մլն
51,31 մլն
27,02 մլն
33,38 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
753,48 մլն
815,96 մլն
721,16 մլն
803,44 մլն
Operating expense
838,57 մլն
897,00 մլն
786,62 մլն
895,87 մլն
Total operating expenses
3,78 մլրդ
3,85 մլրդ
3,96 մլրդ
3,86 մլրդ
Operating income
112,30 մլն
88,76 մլն
219,91 մլն
264,89 մլն
Other non operating income
468,22 հզր
-13,01 մլն
-7,97 մլն
1,21 մլն
EBT including unusual items
119,12 մլն
91,70 մլն
206,43 մլն
311,43 մլն
EBT excluding unusual items
109,94 մլն
63,73 մլն
208,13 մլն
254,28 մլն
Income tax expense
41,30 մլն
34,62 մլն
45,36 մլն
63,42 մլն
Effective tax rate
34,67%
37,75%
21,97%
20,37%
Other operating expenses
24,67 մլն
29,19 մլն
21,94 մլն
53,95 մլն
Net income
68,89 մլն
33,00 մլն
161,13 մլն
249,19 մլն
Net profit margin
1,77%
0,84%
3,86%
6,05%
Earnings per share
-
-
-
-
Interest and investment income
4,05 մլն
3,14 մլն
4,20 մլն
6,12 մլն
Interest expense
-11,05 մլն
-10,76 մլն
-8,01 մլն
-10,10 մլն
Net interest expenses
-7,00 մլն
-7,62 մլն
-3,81 մլն
-3,98 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
166,37 մլն
143,03 մլն
274,17 մլն
320,66 մլն
Gain or loss from assets sale
3,99 մլն
-3,83 մլն
-
-35,83 մլն
AI content may include mistakes. Learn more
Google Apps